ポスター：データからインサイトへ - Genedata Profilerが臨床研究の意思決定をサポートしたRAS阻害剤での活用事例

June 24, 2025

For decades, RAS oncogenes, including HRAS, KRAS, and NRAS, were considered undruggable despite their central role in driving many of the most aggressive cancers. KRAS mutations alone account for 80 percent of all Ras-associated alterations and are linked to lung, colorectal, and pancreatic cancers. Recent advancements in targeted therapies, including KRASG12C inhibitors, represent a turning point, but challenges such as resistance and limited patient eligibility persist. Genedata Profiler enables scientists to harness clinical parameters such as KRAS mutations, biomarker data, demographics, and treatment outcomes to identify optimal indications and responsive patient populations. By integrating treatment data, including circulating tumor DNA levels, the platform uncovers resistance mechanisms and helps determine which patients may benefit from alternative RAS inhibitors versus standard care. By providing access to all relevant datasets across clinical and pre-clinical experiments together with intuitive visualization tools, Genedata Profiler empowers researchers to refine clinical trial design and accelerate therapeutic development. The platform supports precision oncology and ultimately offers new hope to patients facing historically intractable cancers.